Abstract Pemetrexed is a new generation antifolate approved for the treatment of mesothelioma and non-small cell lung cancer. CaVeine is known to augment radiation or chemotherapeutic drug-induced cell killing. The current study addresses the impact of caVeine on the activity of pemetrexed in mesothelioma cell lines. CaVeine enhanced pemetrexed activity in all four mesothelioma cell lines tested (H2052, H2373, H28 and MSTO-211H). CaVeine sensitized H2052 cells in a dose-and schedule-dependent manner, and was associated with a markedly decreased clonogenic survival. CaVeine sensitization occurred only in cells subjected to pulse, but not continuous, exposure to pemetrexed. Similar pemetrexed sensitization was also observed with the clinically better tolerated caVeine analog, theobromine. Pemetrexed sensitization by caVeine was associated with an increase in pemetrexed-induced phosphorylation of ataxia-telangiectasia-mutated (ATM) and Chk1. These data indicate that caVeine and its analog, theobromine, may be a useful approach to enhance pemetrexedbased chemotherapy.
Introduction
Pemetrexed (alimta ® ) is a new generation antifolate with thymidylate synthase as its primary, and glycinamide ribonucleotide formyltransferase as its secondary, target [1] . These are key enzymes required for de novo biosynthesis of thymidine and purine nucleotides. Pemetrexed activity is unlikely to be related to an inhibitory eVect at dihydrofolate reductase because (1) it is a very weak inhibitor of this enzyme (three orders of magnitude less than that of methotrexate), (2) inhibition of thymidylate synthase blocks dihydrofolate production obviating the need for this enzyme and, (3) thymidine alone protects cells from pemetrexed at drug concentrations that markedly suppress tumor cell growth [2] . Pemetrexed, in combination with cisplatin, has been used as front-line treatment of mesothelioma, heretofore considered chemo-resistant [3] . Pemetrexed, alone, is also approved for second-line treatment of non-small-cell lung cancer based upon a recent phase III trial [4] . This drug is currently being evaluated in other cancers, alone or in combination with other agents (http://www.cancer.gov).
CaVeine at sub-or millimolar concentrations, not toxic to cells, enhances the cytotoxic eVect of ionizing radiation. This has been proposed to be based upon an inhibitory eVect on ATM/ATR [5] [6] [7] [8] . Inhibition of ATM/ATR results in abrogation of the G2 cell-cycle check point and cells treated with caVeine undergo mitosis before DNA is repaired [7, 8] . However, AT cells in which ATM is mutated are still sensitized by caVeine, despite the check point defect. This suggests that caVeine eVects cannot be attributed solely to ATM inhibition [9] . Sensitization may also be due to caVeine suppression of homologous recombination-mediated DNA-repair, which is independent of cell cycle signaling, but may accompany caVeine inhibition of ATM [10, 11] . Despite extensive studies on caVeine radiosensitization, caVeine has rarely been used in combination with radiotherapy clinically because of the extent of side eVects associated with sensitizing doses.
CaVeine also sensitizes cancer cells to chemotherapeutics such as nitrogen mustard and thiotepa [12, 13] . Cisplatin sensitization, however, is erratic [14] [15] [16] [17] . CaVeine has been reported to desensitize cells to other DNA-damaging drugs such as mitoxantrone, doxorubicin, camptothecin and topotecan. This has been attributed to formation of complexes between caVeine and these aromatic drugs, which reduces their eVective concentrations [18, 19] . CaVeine has been included in multi-drug regimens for the treatment of malignant melanoma [20] and pancreatic cancer [20] [21] [22] [23] , but enhanced activity has not been documented. However, in other studies the addition of caVeine increased response rates in patients with osteosarcoma, high-grade soft tissue sarcomas, metastatic carcinoma and lymphoma [24] [25] [26] .
In the current study the eVect of caVeine on pemetrexedinduced cell growth inhibition and cell death was assessed in mesothelioma cell lines. In addition, the eVect of theobromine, a clinically more tolerable caVeine analog, on pemetrexed activity was compared to that of caVeine. A pulse exposure to pemetrexed was chosen to simulate the pharmacokinetics of this drug in clinical regimens. With a standard pemetrexed dose of 500 mg/m 2 , the plasma concentration initially reaches more than 200 M but rapidly decreases to 8 M after 8 h and to 0.2 M after 24 h [27] . The eVects of caVeine on ATM autophosphorylation and on phosphorylation of the ATR substrate, Chk1, were also assessed. The results suggest a potential role for agents with caVeine-like actions to augment pemetrexed activity in mesothelioma and other neoplasms.
Materials and methods

Chemicals and reagents
Pemetrexed was provided by the Eli Lilly Company (Indianapolis, IN); caVeine (1,3,7-trimethylxanthine), theobromine (3,7-dimethylxanthine) and anti--actin antibody (clone AC-15, #5441) were obtained from Sigma (St Louis, MO). Antibodies against human phospho-ATM (Serine1981) (#4526) and human phospho-Chk1 (serine317) (#2344) as well as HRP-linked anti-mouse and anti-rabbit IgG were purchased from Cell Signaling Technology (Danvers, MA).
Cells and media
Human mesothelioma cell lines, H2052, H28, and MSTO 211-H, were purchased from the American Type Culture Collection (Manassas, VA); H2373 cells were obtained from the National Cancer Institute. Cells were maintained in RPMI 1640 medium (HyClone, Logan, UT) supplemented with 10% dialyzed fetal bovine serum (Gemini BioProducts, Calabasas, CA), 2 mM glutamine, penicillin (100 units/ml), and streptomycin (100 g/ml) at 37°C in a humidiWed atmosphere of 5% CO 2 .
Cell growth inhibition and clonogenic assay Three diVerent assays were utilized to determine pemetrexed-induced growth inhibition and cell killing in the presence or absence of caVeine.
Pulse exposure to pemetrexed Figure 1 illustrates how a typical experiment with a 2 h-exposure to pemetrexed was performed. Cells were seeded in 12-well plates at a density of 50,000 cells/well and allowed to grow overnight. Unless otherwise speciWed, cells were treated with 30 M pemetrexed for 2 h in the presence or absence of 1 mM caVeine. Pemetrexed was then removed by washing with serum-free medium three times and cells were grown in drug-free medium or medium containing 1 mM caVeine to complete a 2-day treatment with caVeine. Following this, cells were grown in drug-free medium for an additional 3 days before they were trypsinized and cell counts were determined manually on a hemocytometer. Under these conditions cells that were not treated with any drug reached conXuence and only cells that exclude Trypan Blue were scored.
Continuous exposure to pemetrexed
Cells were seeded in 96-well plates (100 l/well) at a density of 1,000 (5-day-exposure) or 3,000 cells/well (3-day Fig. 1 Schedule of pemetrexed pulse exposure in the presence of caVeine and end points for various measurements. Unless otherwise speciWed, this Wgure describes the standard pulse treatment schedule with pemetrexed and caVeine used throughout the studies. Cells were seeded 1 day before they were exposed to pemetrexed and caVeine. Two hours after initiation of pemetrexed (30 M) and caVeine (1 mM) treatment, cells were washed three times with serum-free medium then grown in drug-free medium or medium containing 1 mM caVeine. Two days after the initiation of pemetrexed exposure, cells were replaced with drug-free medium and allowed to grow for an additional 3 days. For growth inhibition assays, cells were usually counted 5 days after pemetrexed treatment. Western blots analysis was performed 8, 24 or 48 h after initiation of pemetrexed and caVeine exposure. Forty-eight hours after initiation of drug exposure, cells were reseeded for clonogenic assays exposure) and grown overnight. Cells were then exposed continuously to pemetrexed and caVeine for an additional 3 or 5 days by introducing an equal volume of medium containing diVerent concentrations of pemetrexed and a constant caVeine concentration of 2 or 4 mM. The Wnal concentration of caVeine was either 1 or 2 mM. Cell growth rate was quantiWed by the sulforhodamine B assay [28] .
Clonogenic assay
Cells were exposed to 30 M pemetrexed for 2 h in the presence or absence of 1 mM caVeine as described above for "pulse exposure to pemetrexed" (see also Fig. 1 ). After 2 days, cells were trypsinized, counted in Trypan Blue solution, and re-seeded in 6-well plates at a density of 200 or 800 viable cells/well. Fourteen days after plating, colonies were Wxed, stained with sulforhodamine B and counted. Clonogenic survival is the ratio (£100) of clones that survived to cells initially seeded.
Western blot
Cells were treated with 30 M pemetrexed for 2 h in the absence or presence of 1 or 2 mM caVeine as illustrated in Fig. 1 . Cells were harvested at 8, 24 and 48 h after initiation of pemetrexed treatment by trypsinization and sonicated (2 to 3-s burst) in a hypotonic buVer (0.5 mM Na 3 PO4, 0.1 mM EDTA, pH 7.4). This was followed by centrifugation at 12,000 rpm for 5 min; supernatants were then collected for Western blot analysis. Protein concentrations were determined by BCA Protein Assay (Pierce, Rockford, IL). Equal amounts of protein (»10 g) were loaded and separated on 12% SDS-PAGE, followed by blotting on a nitrocellulose membrane (Hybond-P, Amersham, Piscataway, NJ). Typically, the membrane was blocked with 5% dry milk in TBS-T (20 mM Tris, 140 mM NaCl, 0.1% Tween-20, pH 7.6) for 1 h and probed with a primary antibody in TBS-T containing 0.5% dry milk for 1 h with a dilution suggested by the manufacturers. The membrane was further incubated with a HRP-linked secondary antibody (1:2000) in TBS-T for 1 h and detected using the Enhanced Chemiluminescence Plus Western Blotting Detection System (GE Healthcare, Buckinghamshire HP7 9NA, UK) and exposed to Kodak Biomax X-ray Wlm (Rochester, NY). For a loading control, the membranes were stripped at 65°C for 30 min in a buVer (62.5 mM Tris, 2% SDS, and 100 mM ß-mercaptoethanol, pH 6.8), and reprobed with an anti--actin antibody.
Flow cytometric determination of DNA content
Cells were seeded in 6-well plates at a density of 0.3 £ 10 6 cells/well 1 day before treatment with "pulse exposure to pemetrexed" as described in Fig. 1 . Cells attached to, or detached from, plates were collected 8, 24 or 48 h after initiation of pemetrexed treatment. The cells were then combined, washed once with PBS, and Wxed with 70% ethanol overnight at 4°C. The cells were pelleted, washed once with PBS and resuspended in 1 ml PBS containing 50 g/ml propidium iodide and 250 g/ml RNase, then incubated at room temperature for 30 min. DNA Xuorescence signals were acquired and analyzed using a FACScan Xow cytometer (Becton Dickinson, Franklin Lakes, NJ) in the Fluorescence Activated Cell Sorting Shared Resource of the Albert Einstein College of Medicine Cancer Center.
Statistical analyses
The data were analyzed by t test (One-tailed paired) or ANOVA (Repeated Measures) analyses provided by Graph Pad Prism software (San Diego, CA).
Results
EVect of caVeine on pemetrexed-induced growth inhibition in mesothelioma cell lines
A pulse exposure to pemetrexed was chosen to study pemetrexed-induced growth inhibition to simulate conditions in which the drug is administered in current clinical regimens. Cells were treated with pemetrexed and caVeine as indicated in Fig. 1 except the interval for pemetrexed exposure was varied from 2 to 8 h. In all four mesothelioma cell lines studied, as the duration of exposure to pemetrexed was increased, the extent of growth inhibition increased (Fig. 2 ). H2052 and H2373 lines were the most sensitive to pemetrexed whereas MSTO-211H cells were the least sensitive among the four cell lines. For example, in the absence of caVeine, incubation with pemetrexed for 8 h reduced cell numbers to 5, 5, 10 or 25% in H2052, H2373, H28 or MSTO-211H cells, respectively. Regardless of the cell line and the pemetrexed exposure time, addition of caVeine during and after pemetrexed exposure signiWcantly reduced cell numbers as compared to pemetrexed treatment alone. The smallest reduction (»50%) was observed with the 2-hpemetrexed exposure in all cell lines, while the largest reduction (»85%) was found with the 8 h-pemetrexed exposure in MSTO-211H cells. CaVeine at this concentration resulted in only a small (10-20%) reduction in cell numbers in the absence of pemetrexed.
Factors that inXuence caVeine sensitization H2052 cells were chosen for further studies to deWne the factors that inXuence caVeine sensitization. To determine the onset of caVeine sensitization, H2052 cells were exposed to pemetrexed for 2 h in the absence or presence of 1 mM caVeine, as illustrated in Fig. 1 , and cell numbers were determined every day for up to 7 days. As indicated in Fig. 3a , 1 mM caVeine alone had little eVect on cell growth. Exposure of H2052 cells to pemetrexed alone for 2 h delayed cell growth by »2 days as compared to untreated cells. The combination of 1 mM caVeine and pemetrexed further delayed cell growth by »2 days. The sensitizing eVect of caVeine could only be discriminated 2 days after pemetrexed treatment.
The eVect of caVeine on pemetrexed-induced growth inhibition was assessed over a caVeine concentration range from 0.25 to 4 mM. At a concentration less than 2 mM, caVeine alone had only a negligible eVect on cell growth; even at 4 mM, caVeine inhibited cell growth only by »30% (Fig. 3b) . However, in the presence of pemetrexed, 1, 2 or 4 mM caVeine decreased cell growth by 72, 92 or 96%, respectively, as compared to cells treated with pemetrexed alone. Sensitization was also detected with caVeine concentrations of 0.25 and 0.5 mM.
The duration of exposure to caVeine required to potentiate pemetrexed activity was also assessed in H2052 cells. As indicated in Fig. 3c , the presence of caVeine in the Wrst 48 hrs after exposure to pemetrexed maximized the synergistic eVect. Extending exposure to caVeine to 72 h did not confer additional sensitization. The Wrst 24 h after initiation of pemetrexed treatment appeared to be crucial to the sensitization eVect of caVeine.
The eVect of caVeine on pemetrexed-induced-growth inhibition with a continuous exposure to pemetrexed was also assessed in H2052 cells. As illustrated in Fig. 3d , neither 1 mM nor 2 mM caVeine had any eVect on pemetrexed activity with a 5-day continuous exposure to pemetrexed. Similar results were obtained when cells were exposed continuously to pemetrexed for 3 days (data not shown).
EVect of caVeine on pemetrexed-induced cell killing determined by clonogenic assay H2052 cells that had been exposed to pemetrexed for 2 h in the absence or presence of 1 mM caVeine were reseeded at the same density 48 h after initiation of pemetrexed treatment (see Figs. 1, 3a) for clonogenic assay. As shown in Fig. 4a and b, 1 mM caVeine alone had no eVect on clonogenicity of H2052 cells in the absence of pemetrexed. Likewise, pemetrexed alone did not reduce clonogenicity as compared to untreated cells, indicating that cells were not killed by the brief exposure to this drug. In contrast, clonogenicity in cells treated with both pemetrexed and caVeine was decreased by 80% as compared to untreated cells or cells treated either with pemetrexed alone, or caVeine alone, indicating that caVeine and pemetrexed were highly synergistic. Hence, the addition of caVeine induced a marked decrease in cell viability generated by pemetrexed.
Comparison of the eVects of caVeine and theobromine on pemetrexed-induced growth inhibition/cell death
The level of caVeine (1 mM), which was required to markedly sensitize cells to pemetrexed, is not clinically feasible due to its neurological side eVects. However, a caVeine analog, theobromine, found in cocoa, is much more clinically 
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Pemetrexed incubation time Percentage of control * * * * tolerable. For example, a single one-gm dose of theobromine has no adverse eVects [29] . Therefore, eVects of caVeine (1 mM) and theobromine (1 mM) on pemetrexed activity were compared. As observed for caVeine, theobromine alone had no eVect on cell growth (P > 0.05) while pemetrexed alone induced »50% inhibition of growth (P < 0.001) (Fig. 5 ). Theobromine and caVeine produced comparable and marked enhancement of pemetrexed activity, each signiWcantly diVerent from the eVects of pemetrexed alone (P < 0.05).
EVects of caVeine on pemetrexed-induced phosphorylation of ATM and Chk1
As illustrated in Fig. 6 , pemetrexed induced autophosphorylation of ATM at serine 1981; the intensity of phosphorylation 24 or 48 h post-pemetrexed treatment was greater than 8 h post-treatment. Regardless of the duration of exposure, 1 mM caVeine markedly increased activation of ATM.
However, when the caVeine concentration was increased from 1 to 2 mM, ATM phosphorylation was decreased to a level comparable to what was observed with pemetrexed alone. The pattern of phosphorylation of Chk1 at serine 317 induced by pemetrexed was quite diVerent. Pemetrexed alone induced Chk1 phosphorylation, but this was gradually decreased as cells recovered after the pemetrexed exposure so that it was barely detectable at 48 h. Addition of caVeine increased phosphorylation of Chk1 in a dosedependent manner. Thus, 1 mM caVeine increased, rather than inhibited, phosphorylation of ATM and Chk1.
EVect of caVeine on pemetrexed-induced cell-cycle arrest in H2052 cells
The eVect of 1 mM caVeine on pemetrexed-induced cell cycle arrest was examined in H2052 cells. As compared to control cells (Fig. 7a ), cells treated with caVeine (1 mM) alone had a normal cell-cycle distribution (data not shown). Fig. 1 . However, cell numbers were determined each day in the experiment starting from day 0 (initiation of pemetrexed treatment); cell growth is expressed as fold increase in cell numbers as compared to day 0. * The diVerence is signiWcant (P < 0.05) as compared to the "pemetrexed only" group. b Treatment of H2052 cells with pemetrexed and caVeine followed the schema in Fig. 1 except that caVeine concentrations were varied from 0.25 to 4 mM. The control represents untreated cells. * The diVerence is statistically signiWcant (P < 0.05) as compared to the respective percentage of control at 0 mM caVeine. c Cells were treated with pemetrexed and caVeine as indicated in Fig. 1 except that the period of caVeine incubation was varied. The control represents cells treated with pemetrexed alone. * Indicates signiWcant diVerence (P < 0.001) from the control. ** Indicates a signiWcant diVerence from the control (P < 0.001) and from the "caVeine (0 to 24 h)" group (P < 0.01). The diVerence between them is not statistically signiWcant (P > 0.05). d H2052 cells were exposed continuously to a spectrum of pemetrexed concentrations and a constant caVeine concentration of either 1 or 2 mM for 5 days. The controls represent cells not exposed to pemetrexed but exposed to the indicated concentrations of caVeine. The data for all panels are the mean § SEM from three independent experiments When cells were exposed to pemetrexed alone for 8 h, a highly lethal condition, they were arrested at early S-phase, and hardly progressed through S-phase before sub-G1 cells emerged after 48 h (Fig. 7b) . However, when cells were treated with pemetrexed alone for only 2 h, a condition that resulted in »50% growth inhibition and used throughout this study, cells were initially arrested in early S-phase but progressed through S-phase and entered G2/M and G1 after 48 h (Fig. 7c) . Inclusion of 1 mM caVeine did not alter the initial S-phase arrest but slightly delayed S-phase progression after 24 or 48 h (Fig. 7d) . This eVect was more evident Fig. 4 EVect of caVeine on clonogenic survival of H2052 cells. H2052 cells were exposed to pemetrexed and caVeine as indicated in Fig. 1 . After 48 h the cells were trypsinized, counted, and reseeded into 6-well plates at a density of 800 or 200 viable cells/well and were allowed to form colonies in drug-free medium over the following 2 weeks. a Represents staining of surviving colonies. The control refers to cells not treated with either drug. b Mean § SEM of three such independent experiments. * Indicates a signiWcant diVerence (P < 0.01) from the other three groups among which there were no signiWcant diVerences (P > 0.05) Western blot analysis of phosphorylation of ATM and Chk1 in H2052 cells exposed to pemetrexed in the presence or absence of caVeine. H2052 cells were exposed to pemetrexed and caVeine as indicated in Fig. 1 with the exception that 2 mM caVeine was also used. Cells were collected by trypsinization and the soluble fractions from cell lysates (»10 g) were prepared in a hypotonic buVer, separated by 12% SDS-PAGE, blotted onto membranes, and probed with antibodies against ATM-p-S1981 and Chk1-p-S137. Each image is representative of at least two independent experiments. The membrane was stripped and re-probed with an antibody against -actin for the loading control. 
Discussion
These studies demonstrate that caVeine markedly sensitizes mesothelioma cells lines to pemetrexed, an eVect that only occurs with pulse, and not continuous, exposure to pemetrexed. Hence, the way in which cells are exposed to these drugs will play a critical role in determining the nature of their interaction and whether there will be any interaction at all. The lack of caVeine sensitization when cells were exposed to pemetrexed continuously indicates that caVeine does not alter the interaction between pemetrexed and its target enzymes. The data also raise the possibility that caVeine sensitization of other drugs may have been underestimated if continuous drug exposure, a widely used condition, was employed. Our data further demonstrate that caVeine sensitization of pemetrexed is due to decreased viability of mesothelioma cells that are only growth-arrested but not killed when treated transiently with pemetrexed alone. There has been a longstanding interest in caVeine as a radio-and chemo-sensitizer, but clinical application of this naturally occurring agent has been largely unexplored. In addition to the lack of incentive for the development of a non-proprietary drug, there have been two major hurdles that have limited the clinical utility of caVeine. (1) There have been conXicting reports on caVeine sensitization of chemotherapeutics in pre-clinical models. (2) The caVeine dose required for sensitization protocols would not be clinically tolerable. The data in the current paper suggest that caVeine sensitization can occur at clinically achievable levels. Administration of 1.5 g/m 2 /24 h caVeine intravenously £ 3 days has tolerable side eVects [26, 30] and plasma caVeine concentrations from 0.2 to 0.4 mM can be sus- tained [30] , levels that sensitize mesothelioma cells to pemetrexed. Our data also raise the possibility that other caVeine analogs that are better tolerated, such as theobromine, may be more feasible, and perhaps more potent, agents to enhance pemetrexed activity.
CaVeine enhancement of pemetrexed activity was prominent in all four mesothelioma cell lines examined despite the fact that all express functional p53 [31] . However, caVeine radiosensitization is less pronounced, or is not observed at all, in cells with functional p53 [32] [33] [34] . This discrepancy may be attributed to diVerences in the eVect of p53 on cell-death induced by radiation and pemetrexed. p53-deWcient tumor cells are radioresistant [32] while pemetrexed induced cell death is independent of p53 function [35] . CaVeine enhancement of pemetrexed activity in p53-competent cells suggests that it has broader applicability than caVeine-enhanced radiation, since greater than 50% of all tumors lose p53 function. It remains to be determined whether p53-defective cells can be sensitized to pemetrexed by caVeine to a greater extent than p53-intact cells.
Although pemetrexed-induced p53 activation has been reported [36] , this is the Wrst report of pemetrexed-induced autophosphorylation of ATM and Chk1, a substrate of ATR. These Wndings are consistent with the mechanism of action of pemetrexed. Pemetrexed primarily inhibits thymidylate synthase, disrupts DNA synthesis, induces DNA doublestrand breaks, and results in phosphorylation of ATM/ATR. However, the increase in pemetrexed-induced phosphorylation of ATM by caVeine is not consistent with the reported inhibitory eVect of caVeine on this signal molecule [5] [6] [7] [8] . It is possible that caVeine suppression of homologous recombination-mediated DNA-repair [10, 11] results in an increase in double-strand breaks in DNA and, in turn, increases phosphorylation of ATM or ATR (super-activation). This is also consistent with our observations that caVeine delays pemetrexed-induced cell cycle progression. Hence, the eVect of caVeine on phosphorylation of ATM depends on two opposing eVects, direct inhibition of phosphorylation and enhanced phosphorylation of this molecule due to an increase in DNA double-strand breaks. Super-activation of ATM or ATR substrates, Chk1 and Chk2, in cells treated with genotoxic agents and caVeine has also been reported [37] . However, the possibility that the interaction between caVeine and pemetrexed may involve other targets cannot be excluded.
